ULTIO.OL - Ultimovacs ASA

Oslo - Oslo Delayed Price. Currency in NOK
117.00
0.00 (0.00%)
At close: 03:00PM CEST
Stock chart is not supported by your current browser
Previous Close117.00
Open117.00
Bid117.00 x N/A
Ask0.00 x N/A
Day's Range117.00 - 117.00
52 Week Range117.00 - 117.00
Volume271
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update

    Oslo, May 10, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its first quarter 2023 results today. First Quarter 2023 Highlights Ultimovacs is well prepared for the data readout from the first two randomized UV1 Phase II studies in malignant melanoma (INITIUM) and metastatic pleural mesothelioma (NIPU).Data from the INITIUM study were previously expected during the first half of 2023, based on historical

  • GlobeNewswire

    Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation

    Oslo, 3 May 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2023 results on Wednesday 10 May 2023. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday 10 May 2023. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the prese

  • GlobeNewswire

    Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma

    It is taking longer than estimated for the patients in the INITIUM study to experience disease progression, which is positive for patientsResults will be disclosed after cancer progression has been verified in 70 patients, which has not yet occurredGuidance for readout is consequently adjusted from the first half to the second half of 2023INITIUM completed enrollment of 156 patients in June 2022, and will provide comparative, randomized data on efficacy of UV1 treatment added to standard of care

  • GlobeNewswire

    Ultimovacs ASA - Share Option Program

    Oslo, 21 April 2023: On the basis of the approval by the General Meeting on 20 April 2023 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to issue new shares to employees under a long-term incentive program, the Board of Directors has resolved to issue share options to employees in the Company. A total of 160,000 options for shares in the Company have been distributed amongst the employees. The number of options granted corresponds to 0.47% of the outstan

  • GlobeNewswire

    Ultimovacs ASA – Annual General Meeting held on 20 April 2023

    Oslo, 20 April 2023: Ultimovacs ASA held its annual general meeting today 20 April 2023. All the matters on the agenda were approved. All board members were re-elected for a period of one year, and the Board of Directors will continue to consist of the following persons: Jónas Einarsson, Chair of the BoardKari Grønås, board memberEva S. Dugstad, board memberLeiv Askvig, board memberKetil Fjerdingen, board memberHenrik Schüssler, board memberAitana Peire, board memberHaakon Stenrød, board member

  • GlobeNewswire

    Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting

    Oslo, 14 April 2023: In connection with the Annual General Meeting of Ultimovacs ASA to be held on 20 April 2023, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting rights without voting instructions for 11,364,278 shares, representing 33.04% of the total voting rights in the company. With the addition of the 1,512,163 3 shares controlled by Radforsk, Jónas Einarsson thus represents a total of 12,876,441 shares. This corresponds to 37.44% of the company's to

  • GlobeNewswire

    Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations

    Protects UV1 vaccine-checkpoint inhibitor combinations in cancer until at least 2037Covers UV1 combined with CTLA-4, PD-1 or PD-L1 checkpoint inhibitorsNotice of intention to grant received in Europe. Corresponding patent granted in the US, additional applications pending Oslo, 13 April 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, received a Notice of Intention to Grant from the European Patent Office (EPO) concerning its Euro

  • GlobeNewswire

    Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023

    Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") in the meeting room ‘Jónas Einarsson auditorium’ in Ullernchausséen 64, 0379 Oslo, at 14:00 CET on 20 April 2023. All documents regarding the Annual General Meeting are available at the Company’s website: www.ultimovacs.com For further information, please see www.ultimovacs.com or contact: Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA Email: je@radfors

  • GlobeNewswire

    Ultimovacs ASA: Annual Report 2022

    Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2022. Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: www.ultimovacs.com This informat

  • GlobeNewswire

    Ultimovacs to Present at Cowen Healthcare Conference

    Oslo, February 27, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces today that Carlos de Sousa, Chief Executive Officer and Jens Bjørheim, Chief Medical Officer, will present Ultimovacs at the Cowen Healthcare Conference on Monday, March 6 at 2:50 PM (EST). A webcast of the presentation will be available on the Company website. Cowen’s 43rd Annual Health Care Conference is taking place March 6 - 8, 2023, a

  • GlobeNewswire

    Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update

    Oslo, February 16, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its fourth quarter 2022 results today. Fourth Quarter 2022 Highlights Ultimovacs is on track to Phase II clinical trial readouts; topline results continue to be expected during the first half of 2023 from the first two randomized Phase II clinical trials, INITIUM in malignant melanoma and NIPU in metastatic pleural mesothelioma.The INITIUM

  • GlobeNewswire

    Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

    Full recruitment of 118 patients with mesothelioma in Scandinavia, Spain and AustraliaThe study provides randomized data on impact of UV1 in combination with checkpoint inhibitors ipilimumab and nivolumabTopline progression-free survival data expected H1 2023 Oslo, 23 January 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces the completed recruitment of 118 patients with pleural mesothelioma in the NIPU tri

  • GlobeNewswire

    Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial

    Oslo, 20 December 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced today that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor in combination with UV1 in the Phase II randomized LUNGVAC trial rather than pembrolizumab (Keytruda). The move, which will be implemented January 1, 2023, follows the decision by the Norwegian Health Authorities of reimbursement of cemiplimab for monotherapy or f

  • GlobeNewswire

    Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer

    First clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technologyFirst clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technology12 patients with prostate cancer treated in TENDU studyStudy provides immune activation and safety data important for future clinical development within the TET technology Oslo, 14 December 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announce

  • GlobeNewswire

    Ultimovacs ASA: Mandatory notification of trade by primary insider

    Oslo, 29 November 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,500 shares in the company at an average price of NOK 96.7058 per share. Following this transaction, Carlos de Sousa and closely related parties hold 21,556 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegia

  • GlobeNewswire

    Ultimovacs ASA: New share capital registered

    Oslo, 21 November 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 16 November 2022 regarding the issuance of new shares in connection with the Company's employee incentive program. The share capital increase related to the share issue of 130,700 new shares has been registered in the Norwegian Register of Business Enterprises, and the Company's new share capital is NOK 3,439,646.10, divided into 34,396,461 shares, each with a par value of NOK 0.10. For further informa

  • GlobeNewswire

    Ultimovacs ASA: Share capital increase related to exercise of options

    Oslo, 16 November 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital, related to the exercise of options, by NOK 13,070 through the issuance of 130,700 new shares, each with a par value of NOK 0.10. The resolution is based on an authorisation to increase the share capital granted by the Company's general meeting on 21 April 2022. Following the option exercise, 2,138,885 options are outstanding. The new shares are issued to employee

  • GlobeNewswire

    Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update

    Oslo, November 10, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2022 results today. Third Quarter 2022 Highlights: Ultimovacs is getting close to key value inflection points: Readouts from the first two UV1 phase II studies in combination with checkpoint inhibitors, INITIUM and NIPU, are expected during the first half of 2023Good patient enrollment continues across Ultimovacs’ phase II program, incl

  • GlobeNewswire

    Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation

    Oslo, 3 November 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its third quarter 2022 results on Thursday 10 November 2022. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Thursday 10 November 2022. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the present

  • GlobeNewswire

    Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

    Fifth phase II trial assessing the impact of UV1 in various immunotherapy combinationsEnrollment of 138 patients at approximately all lung cancer centers in NorwayNon-small cell lung cancer is one of the largest cancer indications globally Oslo, October 25 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today that the first patient has been randomized in the LUNGVAC study. The study in non-small cell lung cancer (NSCLC)

  • GlobeNewswire

    Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

    Malignant melanoma patients treated with immunotherapy combination UV1 and pembrolizumab in phase I clinical trialConsistently high overall survival (OS) rate: 71% at three-year follow-up of patients in first cohortUV1 and pembrolizumab combination continues to demonstrate strong signals of clinical efficacy, including prolonged patient survival Oslo, 5 October 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced continuing

  • GlobeNewswire

    Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

    Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trialClinical responses seen in patients with favored and less favored baseline characteristicsT cell activation observed post-treatment in tumors of responding patients Oslo, September 12, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for the treatment of cancer, announced today the publication of data from its phase I melanoma trial in Journal of Translational

  • GlobeNewswire

    Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent

    Will cover methods for eliciting T cell immune responseProtects US sales and marketing of UV1 Oslo, August 22, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for the company’s US application 15/498,728 for a patent covering methods for eliciting a T cell immune response with the UV1 universal cancer vaccine. Subject to gra

  • GlobeNewswire

    Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update

    Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2022 results today. The presentation by the company's management team can be followed as a live webcast at 09:00 CET and will be made available on the website. It will be possible to post questions during the presentation through the webcast. Highlights of Second Quarter 2022 and Recent Business, Clinical and Research Progress On 30 June

  • GlobeNewswire

    Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review

    The TENDU interim safety results from nine patients show no safety concernsTrial extended to enroll up to three additional patients at the highest dose levelTENDU designed to evaluate the Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer Oslo, 18 August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any